Hepatic fatty acid and cholesterol synthesis enzymes

Hepatic fatty acid and cholesterol synthesis enzymes represent a collective group of catalytic proteins responsible for the de novo production of lipids within the liver. Key enzymes in these pathways include 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, which governs the rate-limiting step of cholesterol synthesis (StatPearls, 2023), and Acetyl-CoA carboxylase (ACC) and Fatty acid synthase (FAS), which regulate the synthesis of long-chain fatty acids (Loomba et al., 2021). These enzymes are vital for maintaining cellular membrane integrity and energy storage; however, their dysregulation is a primary driver of metabolic syndromes, including non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia (NIH, 2021). Therapeutic strategies targeting these enzymes, such as statins for HMG-CoA reductase or novel inhibitors like firsocostat for ACC and denifanstat for FAS, aim to lower circulating lipid levels and reduce hepatic steatosis (Sagimet Biosciences, 2024). Despite their efficacy, pharmacological intervention must balance the reduction of harmful lipids with the maintenance of essential metabolic functions to avoid adverse effects like muscle toxicity or systemic metabolic imbalances.

Other names

De novo lipogenesis (DNL) enzymesHepatic lipid biosynthetic enzymesSterol and fatty acid synthesis pathway

Drugs targeting these enzymes act by inhibiting the catalytic activity of rate-limiting steps in lipid biosynthesis. For instance, statins inhibit HMG-CoA reductase to block the mevalonate pathway (StatPearls, 2023), while ACC inhibitors like firsocostat prevent the conversion of acetyl-CoA to malonyl-CoA, thereby reducing substrate availability for fatty acid synthesis and increasing fatty acid oxidation (Loomba et al., 2021).